CX3CL1 and colitis: The knockout/blockade of fractalkine attenuated mucosal inflammation in murine colitis models and showed a moderate clinical response in CD patients (Wakita et al., 2017; Kuboi et al., 2019; Tabuchi et al., 2019; Matsuoka et al., 2021).